CareDx, Inc. (CDNA)
CDNA moved a median of -0.14% 30 minutes after news, and +0.29% by the close. How CDNA actually reacts to news — the realized, point-in-time move the market made, measured across 447 labeled events over the last three years with zero look-ahead.
CDNA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.03% | 47% | 447 |
| 30-min | -0.14% | 47% | 447 |
| 60-min | -0.11% | 46% | 447 |
| to close | +0.29% | 53% | 442 |
| Middle 50% of CDNA reactions | -1.29% to +1.46% |
|---|---|
| Median reaction (30-min) | -0.14% |
| Measured reactions | 447 |
Half of all CareDx, Inc. news events land between -1.29% and +1.46% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CDNA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 32 | +0.87% | 59% | +1.03% |
| Analyst downgrades | 19 | -0.34% | 42% | +0.32% |
| Rating reiterations | 51 | -0.07% | 43% | +0.16% |
| Price-target raises | 12 | -0.46% | 42% | -0.31% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how CDNA ranks against every other measured name →
That’s how CDNA usually reacts — get an email when it moves on news →Email me when CDNA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CDNA's baseline. Nothing else.
Recent CDNA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.47% | — | |
| CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -2.89% | +1.03% | |
| CareDx Announces Second Quarter 2026 Financial Results | Press release | Business Wire | -0.89% | +2.85% | |
| Form 10-Q CareDx, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.89% | +2.85% | |
| Form 8-K CareDx, Inc. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -0.89% | +2.85% | |
| Form S-8 CareDx, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.89% | +2.85% | |
| CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination | Press release | Business Wire | +1.08% | +10.82% | |
| CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026 | Press release | Business Wire | +1.08% | +10.82% | |
| Form 8-K CareDx, Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +0.87% | -1.32% | |
| CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology | Press release | Business Wire | -0.17% | -2.11% | |
| CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific | Press release | Business Wire | +0.73% | +1.88% | |
| CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress | Press release | Business Wire | +1.02% | +9.40% | |
| CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology | Press release | Business Wire | -0.77% | +0.73% | |
| Form 8-K CareDx, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -0.71% | -3.49% | |
| Form DEFA14A CareDx, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.09% | -1.35% | |
| CareDx to Participate in Upcoming Investor Conferences | Press release | Business Wire | -0.90% | +2.32% | |
| CareDx Announces Dismissal of 2021 Qui Tam Suit | Press release | Business Wire | +1.65% | -0.60% | |
| CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.39% | -2.78% | |
| CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing | Press release | Business Wire | +0.90% | -7.02% | |
| CareDx Announces First Quarter 2026 Financial Results | Press release | Business Wire | +0.90% | -7.02% | |
| Form 10-Q CareDx, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.90% | -7.02% | |
| Form 8-K CareDx, Inc. For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | +0.90% | -7.02% | |
| Form S-3ASR CareDx, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | +0.90% | -7.02% | |
| Form ARS CareDx, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.14% | +0.83% | |
| Form DEF 14A CareDx, Inc. For: Apr 27 | SEC filing · Form DEF | SEC EDGAR | +0.14% | +0.83% | |
| Form DEFA14A CareDx, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.14% | +0.83% | |
| Form 8-K/A CareDx, Inc. For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | -0.30% | +5.10% | |
| CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation’s 46th Annual Meeting | Press release | Business Wire | -0.85% | -2.41% | |
| CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing | Press release | Business Wire | -0.07% | -0.56% | |
| Form 8-K CareDx, Inc. For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | -1.25% | +6.16% | |
| CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results | Press release | Business Wire | -1.25% | +6.16% | |
| CareDx to Report First Quarter 2026 Financial Results on April 28, 2026 | Press release | Business Wire | +0.57% | -0.57% | |
| CareDx Announces VANTx™, an AI-Powered Clinical Data & Analytics Platform Built on CareDx’s Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets | Press release | Business Wire | -1.47% | -2.45% | |
| CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +2.58% | +1.60% | |
| Form 10-K CareDx, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.68% | +0.16% | |
| Form 8-K/A CareDx, Inc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | -1.68% | +0.16% | |
| CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer | Press release | Business Wire | +5.77% | +8.08% | |
| CareDx Announces Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | +5.77% | +8.08% | |
| Form 8-K CareDx, Inc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +5.77% | +8.08% | |
| CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference | Press release | Business Wire | -0.03% | +2.05% | |
| CareDx Announces Clinical Validation Results for AlloHeme™, the First AI-Powered NGS Surveillance Solution for AML and MDS Post-Cell Therapy | Press release | Business Wire | +0.04% | -4.97% | |
| CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 | Press release | Business Wire | +0.07% | -5.05% | |
| CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings | Press release | Business Wire | +0.19% | -1.29% | |
| CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference | Press release | Business Wire | -0.96% | -1.59% | |
| CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | +6.29% | +14.60% | |
| Form 8-K CareDx, Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +6.29% | +14.60% | |
| CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response | Press release | Business Wire | +1.98% | -0.47% | |
| CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.20% | -1.79% | |
| CareDx Provides Notice of Proposed Derivative Settlement | Press release | Business Wire | +0.52% | +1.04% | |
| Form 8-K CareDx, Inc. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +0.52% | +1.04% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CDNA section they belong to.
Where else CDNA is measured.
CDNA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cosmos Health Inc. (COSM) | 451 | 0.00% | 49% |
| HCA Healthcare, Inc. (HCA) | 449 | +0.30% | 63% |
| Medtronic plc. Ordinary Shares (MDT) | 446 | -0.10% | 44% |
| KalVista Pharmaceuticals, Inc. (KALV) | 444 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CareDx, Inc.'s median reaction calculated?
Every labeled CDNA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 447 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of CDNA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does CDNA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.